Cagent Vascular Completes Enrollment of PRELUDE Study Using Serranator Device

June 5th, 2017

WAYNE, Pa. –(BUSINESS WIRE)–  Cagent Vascular, a developer of next generation technology for vessel dilatation in cardiovascular disease interventions, including the FDA 510(k) cleared Serranator® Alto PTA Serration Balloon Catheter, announces the completion of enrollment in the First-in Human PRELUDE Study. The purpose of this prospective, single-arm, multicenter feasibility study is to show the safety and

Read More

Cagent Vascular Announces FDA 510(k) Clearance of Next Generation Device for Vessel Dilatation in Peripheral Artery Disease Interventions

February 27th, 2017

WAYNE, Pa.–(BUSINESS WIRE)—Cagent Vascular, a developer of next generation technology for vessel dilatation in cardiovascular disease interventions, announces FDA 510(k) Clearance of its lead product, the Serranator™ Alto PTA Serration Balloon Catheter.   The Serranator™ is the first of a family of peripheral artery disease (PAD) technologies under development which incorporate proprietary Serration Technology to an

Read More